Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and it's an element you can count on ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...

Four-star-rated analyst Daniel Grosslight at Citi reiterated his Sell rating on Hims & Hers Health (HIMS) stock yesterday, ...

Tirzepatide is part of a class of drugs known ... Now, let's get back to our question: Is Eli Lilly a buy? It's true that competition in the weight loss drug market is a risk, but there's reason ...

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong ...

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...

“The agency in October ended the tirzepatide injection shortage prematurely ... consumers who lack insurance coverage the option to buy Zepbound and Wegovy, respectively, on direct-to-consumer ...

who worries the supply cutoff will force her to buy the brand-name version of a drug she can't afford. She takes a compounded version of tirzepatide, Eli Lilly's drug sold under the name Mounjaro ...